0000874015-19-000057.txt : 20190405 0000874015-19-000057.hdr.sgml : 20190405 20190405192914 ACCESSION NUMBER: 0000874015-19-000057 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190403 FILED AS OF DATE: 20190405 DATE AS OF CHANGE: 20190405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: O'NEIL PATRICK R. CENTRAL INDEX KEY: 0001564926 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19125 FILM NUMBER: 19736200 MAIL ADDRESS: STREET 1: C/O ISIS PHARMACEUTICALS, INC. STREET 2: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330336973 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 FORMER COMPANY: FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2019-04-03 0000874015 IONIS PHARMACEUTICALS INC IONS 0001564926 O'NEIL PATRICK R. C/O IONIS PHARMACEUTICALS, INC. 2855 GAZELLE COURT CARLSBAD CA 92010 0 1 0 0 SVP Legal & General Counsel Common Stock 2019-04-03 2019-04-03 4 M 0 7654 61.68 A 27327 D Common Stock 2019-04-03 2019-04-03 4 S 0 7654 84.83 D 19673 D Common Stock 2019-04-04 2019-04-04 4 M 0 15492 61.68 A 35165 D Common Stock 2019-04-04 2019-04-04 4 S 0 15492 84.75 D 19673 D Common Stock 2019-04-04 2019-04-04 4 M 0 4873 61.68 A 24546 D Common Stock 2019-04-04 2019-04-04 4 S 0 4873 82.19 D 19673 D Common Stock 2019-04-04 2019-04-04 4 M 0 2657 61.57 A 22330 D Common Stock 2019-04-04 2019-04-04 4 S 0 2657 82.03 D 19673 D Common Stock 2019-04-04 2019-04-04 4 M 0 2000 47.34 A 21673 D Common Stock 2019-04-04 2019-04-04 4 S 0 2000 84.20 D 19673 D Common Stock 2019-04-04 2019-04-04 4 M 0 3600 47.34 A 23273 D Common Stock 2019-04-04 2019-04-04 4 S 0 3600 82.10 D 19673 D Common Stock 2019-04-04 2019-04-04 4 M 0 8000 49.25 A 27673 D Common Stock 2019-04-04 2019-04-04 4 S 0 8000 84.29 D 19673 D Common Stock 2019-04-04 2019-04-04 4 S 0 1122 82.01 D 18551 D Common Stock 2019-04-04 2019-04-04 4 S 0 1878 84.25 D 16673 D Common Stock 2019-04-05 2019-04-05 4 M 0 2252 61.68 A 18925 D Common Stock 2019-04-05 2019-04-05 4 S 0 2252 84.75 D 16673 D Employee Stock Option (right to buy) 61.68 2019-04-03 2019-04-03 4 M 0 7654 0 A 2019-01-04 2023-01-03 Common Stock 7654 30586 D Employee Stock Option (right to buy) 61.68 2019-04-04 2019-04-04 4 M 0 20365 0 A 2019-01-04 2023-01-03 Common Stock 20365 10221 D Employee Stock Option (right to buy) 61.57 2019-04-04 2019-04-04 4 M 0 2657 0 A 2019-01-02 2022-01-01 Common Stock 2657 0 D Employee Stock Option (right to buy) 47.34 2019-04-04 2019-04-04 4 M 0 5600 0 A 2019-01-03 2024-01-02 Common Stock 5600 20825 D Employee Stock Option (right to buy) 49.25 2019-04-04 2019-04-04 4 M 0 8000 0 A 2019-01-02 2025-01-01 Common Stock 8000 46638 D Employee Stock Option (right to buy) 61.68 2019-04-05 2019-04-05 4 M 0 2252 0 A 2019-01-04 2023-01-03 Common Stock 2252 7969 D Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.75 to $85.025, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plans adopted by the reporting person on 8/29/2018 and 3/5/2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.05 to $82.30, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.00 to $82.05, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) on this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.20 to $84.35, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) on this Form 4. The sale was made pursuant to shares owned. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.00 to $82.02, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (9) on this Form 4. Patrick R. O'Neil 2019-04-05